Clinical Trials Logo

Bacterial Infections clinical trials

View clinical trials related to Bacterial Infections.

Filter by:

NCT ID: NCT03774940 Completed - Nephrolithiasis Clinical Trials

Blood Parameters as a Predictor of Fever After Percutaneous Nephrolithotomy

Start date: January 1, 2005
Phase: N/A
Study type: Interventional

To investigate the relationship between neutrophil count, lymphocyte count, neutrophil-to-lymphocyte count ratio (NLR), and postoperative fever in patients undergoing percutaneous nephrolithotomy (PNL).

NCT ID: NCT03767374 Recruiting - HIV Infections Clinical Trials

Risk-factors for Multidrug-resistant Bacteria Colonization Among Patients at High Risk of STIs

BMR-IST
Start date: May 11, 2018
Phase:
Study type: Observational

The aim of this study is to identify risk factors and prevalence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria colonization among patients at high risk of STIs

NCT ID: NCT03761043 Not yet recruiting - Clinical trials for Bacterial Infections

Nurse Promotion of IV to PO Antimicrobial Conversion

FERN-IPO
Start date: January 2019
Phase: N/A
Study type: Interventional

This is a prospective, quasi-experimental, historically controlled study to evaluate if a behavioural change intervention informed by the COM-B model of behaviour change can improve nurses' self-perceived capability, opportunity, and motivation to engage in the assessment of patients who may be appropriate for IV to PO antimicrobial conversion. This study also seeks to determine if this translates into an increase in IV to PO antimicrobial conversion rates in the acute care setting.

NCT ID: NCT03752476 Not yet recruiting - Clinical trials for Antibiotic Resistant Infection

Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria

INOR Blact
Start date: January 1, 2019
Phase:
Study type: Observational

This study evaluates the impact of rank of Beta lactam antibiotics on emergence of mutlidrug resistant bacteria colonization in intensive care It's retrospective case controle study. Cases are colonized patient by multidrug resistant bacteria hospitalized in intensive care during the fist hospitalization in intensive care. Temoin are patients with the same characteristics than case but no colonized by multidrug resistant bacteria.

NCT ID: NCT03752424 Recruiting - Clinical trials for Infection, Bacterial

Topical Silver Nanoparticles for Microbial Activity

Start date: January 13, 2019
Phase: Phase 1
Study type: Interventional

Silver nanoparticles are one of most nanoparticles use nowadays in the research area because it has specific physical and chemical properties, in medical fields silver nanoparticles can involve in diagnostic and treatment processes. Silver nanoparticles have antibacterial, antiviral, antifungal, antiangiogenic, antioxidant, cosmetics, antitumor, anti-inflammatory, the drug carrier, imaging, water treatment, and biosensing effects. Silver nanoparticles prepared with reducing agent tri-sodium citrate then incorporated in a topical cream to obtain a significant inhibition of the bacterial strains, inhibition of growth of bacterial strains in the face or other parts in the bodies.

NCT ID: NCT03747497 Not yet recruiting - Clinical trials for Gram-Positive Bacterial Infections

Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

Start date: November 15, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether contezolid acefosamil is as safe and effective as linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections

NCT ID: NCT03738683 Not yet recruiting - Clinical trials for Bacterial Infections

Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients

PICTAR
Start date: December 1, 2018
Phase:
Study type: Observational

Optimal understanding of piperacillin-tazobactam pharmacokinetics in critically ill patients is lacking resulting in large variation of achieved exposure and possible inadequate therapy. The investigators hypothesize that drug dosing based on CKD-EPIcr-cys provides a useful method to individualize and optimize therapy for piperacillin-tazobactam and eventually improve outcome. In a multi-centre, observational, open-label study the investigators aim to define PK of free drug concentrations of both piperacillin and tazobactam in ICU patients and define a PK model for estimation of renal function that most accurately predicts piperacillin and tazobactam clearance.

NCT ID: NCT03726216 Recruiting - Clinical trials for Bacterial Infections

Xydalba Utilization Registry in France

Start date: September 6, 2018
Phase:
Study type: Observational [Patient Registry]

This observational study will collect data on the use of the drug Xydalba® in daily clinical practice in France. Such observational studies are also referred to as registries. The sponsor of the study is Correvio International Sárl, based in Switzerland. Xydalba® contains the active substance dalbavancin, a remedy for a certain type of bacterial pathogens (so-called "gram positive bacteria") which cause the disease. Active ingredients against bacteria are also called antibiotics. Correvio wants to know which patients received the drug and how the disease went. The treatment places where you got Xydalba, ie clinic, intensive care unit or elsewhere should be recorded. In addition, it is important in this type of medication to track whether the pathogens are changing in any way. Any safety-relevant events (such as side effects) that have occurred during treatment should be investigated by the sponsor and submitted to the competent European authorities.

NCT ID: NCT03721146 Recruiting - Immune Deficiency Clinical Trials

ENCAPSID Study : ENCApsulated Bacterial Infection and Primary, Secondary ImmunoDeficiency

ENCAPSID
Start date: September 1, 2018
Phase:
Study type: Observational

Background : The occurrence of Primary immune deficiencies (PID) is rare in adults. Antibody deficiencies were the first PID to be diagnosed in adulthood and are mainly represented by common variable immune deficiency. The main manifestation of these PID are encapsulated bacterial infection which used to be recurrent and/or invasive, lead to hospitalization and have high rates of morbidity and mortality. Diagnosis of PID in adulthood may be supported by six warning signs from the European Society of Immunodeficiencies (ESID). However, their guidelines do not comprehensively describe symptoms of PID, even for patients with infections. The guidelines recommend screening adults for PID after at least two severe bacterial infections. The aim of this study is to screen for PID adult admitted to our hospital for encapsulated infection without any predisposal factor. Material and methods : - Monocentric study. Inclusion between September 218 and September 2021 - Inclusion criteria : 1. Age 18 to 65 years old 2. Invasive encapsulated infection (Streptococcus pneumoniae, Streptococcus pyogènes, Haemophilus influenzae, Neisseiria meningitidis or Neisseria gonorrhoeae ) - Exclusion criteria : 1. Medical history of PID 2. Medical history of Secondary immune deficiency (SID) 3. Local-regional factor that could predispose them to infection 4. Hospital-acquired infection - PID screening included the following: complete blood count, blood smear, immunoglobulin (Ig) isotype (IgA,M, G) and IgG subclass levels, total hemolytic complement and complement fractions (C) 3 and 4, alternative complement pathway (AP50) in case of Neisseria meningitidis (NM) infection, quantitative immunophenotyping of T, B and natural killer cells, specific antibody response to diphtheria, tetanus and pneumococcal vaccine and HIV serology. The clinical and laboratory diagnostic criteria used to identify PID were based on guidelines from the ESID and the Pan-American Group for Immunodeficiency (PAGID) - A consultation in the infectious Diseases Department or Internal Medicine will be scheduled the hospitalization 3 months later to include patients and perform PID screening.

NCT ID: NCT03696901 Not yet recruiting - Clinical trials for Bacterial Infections

Xydalba Utilization Registry in Germany

Start date: October 2018
Phase:
Study type: Observational

This observational study will collect data on the use of the drug Xydalba® in daily clinical practice in Germany. Such observational studies are also referred to as registries. The sponsor of the study is Correvio International Sárl, based in Switzerland. Xydalba® contains the active substance dalbavancin, a remedy for a certain type of bacterial pathogens (so-called "gram positive bacteria") which cause the disease. Active ingredients against bacteria are also called antibiotics. Correvio wants to know which patients received the drug and how the disease went. The treatment places where you got Xydalba, ie clinic, intensive care unit or elsewhere should be recorded. In addition, it is important in this type of medication to track whether the pathogens are changing in any way. Any safety-relevant events (such as side effects) that have occurred during treatment should be investigated by the sponsor and submitted to the competent European authorities.